Drug Approval | September 03, 2021
Covid-19 vaccine clinical trial for people with autoimmune disease
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Subscribe To Our Newsletter & Stay Updated
